Biopharmaceutical company Radiation Control Technologies (RCTI) has been granted an exclusive license to two patents from the U.S. National Institutes of Health (NIH).
The license covers the composition and uses of the company's RCT1938 agent worldwide as a radiosensitizer to treat cancer and to treat or prevent radiation exposure in humans, RCTI said.
RCTI is entering into advanced preclinical testing of RCT1938 as an adjuvant for radiotherapy and is seeking federal grants and contracts to develop RCT1938 as a radiation medical countermeasure.
RCT1938 is derived from a chemical class that has been proven safe in clinical trials, according to the company.
